Next Article in Journal
The Tumor Microenvironment in Colorectal Cancer Therapy
Next Article in Special Issue
Multifaceted Regulation of PTEN Subcellular Distributions and Biological Functions
Previous Article in Journal
Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies
Previous Article in Special Issue
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
Open AccessReview

The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma

1
UOC Anatomia Patologica, San Camillo De Lellis, 02100 Rieti, Italy
2
UOC di Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Agostino Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy
3
Istituto di Clinica Ostetrica e Ginecologica, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(8), 1169; https://doi.org/10.3390/cancers11081169
Received: 15 June 2019 / Revised: 26 July 2019 / Accepted: 8 August 2019 / Published: 14 August 2019
(This article belongs to the Special Issue PTEN: A Multifaceted Tumor Suppressor)
Soft tissue sarcoma (STS) is a rare malignancy of mesenchymal origin classified into more than 50 different subtypes with distinct clinical and pathologic features. Despite the poor prognosis in the majority of patients, only modest improvements in treatment strategies have been achieved, largely due to the rarity and heterogeneity of these tumors. Therefore, the discovery of new prognostic and predictive biomarkers, together with new therapeutic targets, is of enormous interest. Phosphatase and tensin homolog (PTEN) is a well-known tumor suppressor that commonly loses its function via mutation, deletion, transcriptional silencing, or protein instability, and is frequently downregulated in distinct sarcoma subtypes. The loss of PTEN function has consequent alterations in important pathways implicated in cell proliferation, survival, migration, and genomic stability. PTEN can also interact with other tumor suppressors and oncogenic signaling pathways that have important implications for the pathogenesis in certain STSs. The aim of the present review is to summarize the biological significance of PTEN in STS and its potential role in the development of new therapeutic strategies. View Full-Text
Keywords: PTEN; Soft tissue sarcoma; liposarcoma; leiomyosarcoma; malignant peripheral nerve sheath tumor; undifferentiated pleomorphic sarcoma; myxofibrosarcoma; gastrointestinal stromal tumor; epithelioid sarcoma; synovial sarcoma PTEN; Soft tissue sarcoma; liposarcoma; leiomyosarcoma; malignant peripheral nerve sheath tumor; undifferentiated pleomorphic sarcoma; myxofibrosarcoma; gastrointestinal stromal tumor; epithelioid sarcoma; synovial sarcoma
Show Figures

Figure 1

MDPI and ACS Style

Stefano, S.; Giovanni, S. The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma. Cancers 2019, 11, 1169.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Cancers, EISSN 2072-6694, Published by MDPI AG
Back to TopTop